The global small molecule drug discovery market size is anticipated to expand at a robust CAGR during the forecast period, 2021-2028. The growth of the market is attributed to rising applications of small molecule drugs in the treatment of chronic disorders. Moreover, increasing prevalence of chronic diseases is anticipated to propel the market growth.
Small molecule drugs are compounds with low molecular weight that are capable of modulating biochemical processes to diagnose, treat, or prevent diseases. These drugs include aspirin, diphenhydramine, and aripiprazole.
Request Free Sample Report Here
Small molecule drugs have organic compounds and metabolites. When the biological target is well defined and understood, the rational design of small molecule ligands is possible. Moreover, small molecule libraries are also used for unbiased assays of complex diseases in which biological target is unknown or multiple factors contribute to the disease.
Market Trends, Drivers, Restraints, and Opportunities:
- Rising technological advancements and growing preference for small molecules are some of the key drivers that are contributing to the growth of the global small molecule drug discovery market.
- Rising disease complications have led major players to increase their R&D expenditure, which in turn, is expected to augment the small molecule drug discovery market growth.
- High drug development cost can hinder the market growth.
- The outbreak of COVID-19 has positively impacted the small molecule drug discovery market. This is due to the increasing burden on the healthcare industry, which encouraged government to increase their health expenditure.
- Rising trend of increasing small molecule-based pipeline drug can create lucrative opportunities for industry players in the projected timeline.
Small Molecule Drug Discovery Market Segment Insights:
Oncology segment to grow at a rapid pace
Based on therapeutic areas, the market is divided into oncology, central nervous system, cardiovascular, respiratory, metabolic disorders, gastrointestinal, orthopedics, anti-infective, dermatology, immunology, and others. The oncology segment is anticipated to account for a key market share and is anticipated to grow at a steady rate during the forecast period. Increasing incidence of cancer and ongoing discoveries of small molecule drugs for cancer treatment are expected to propel the growth of the segment.
Lead identification segment to account a major market share
Based on process/phase, the market is divided into target ID/validation, hit generation and selection, lead identification, and lead optimization. The target ID/validation segment is anticipated to account for a major share owing to increasing awareness about its benefits such as identifying and accessing the chances of a molecular target in achieving the development of pharmaceuticals for therapeutic application.
North America to account a considerable market share
On the basis of regions, the market is segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is anticipated to account for a considerable market share owing to presence of major pharmaceutical companies that are engaging in R&D activities and are collaborating with government agencies to develop small molecule drugs in order to meet future health crisis.
Compititive Landscape
The major players of the market are Pfizer Inc., Bristol-Myers Squibb Company, Merck KGaA, Boehringer Ingelheim GmbH, and GlaxoSmithKline. Companies are focusing on innovations, partnerships, and acquisitions to expand their market share.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
The global Small Molecule Cancer Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
The objectives of this study are to define, segment, and project the size of the Small Molecule Cancer Drug market based on company, product type, end user and key regions.
This report studies the global market size of Small Molecule Cancer Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Small Molecule Cancer Drug in these regions.Report Sample includes:- Table of Contents- List of Tables & Figures- Charts- Research MethodologyGet FREE Sample of Small Molecule Cancer Drug Market Report This research report categorizes the global Small Molecule Cancer Drug market by top players/brands, region, type and end user.
This report also studies the global Small Molecule Cancer Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:BayerCadila PharmaceuticalAstrazenecaJohnson & JohnsonEli LilyBoehringerRocheMerckNovartisMarket size by Product CytokineHumanized Monoclonal AntibobyOthers Market size by End User LymphomaMyelomaProstate CancerOthers Market size by Region North AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaSingaporeMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalySpainRussiaCentral & South AmericaBrazilRest of Central & South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth Africa The study objectives of this report are: To study and analyze the global Small Molecule Cancer Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.To understand the structure of Small Molecule Cancer Drug market by identifying its various subsegments.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).Focuses on the key global Small Molecule Cancer Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.To project the value and sales volume of Small Molecule Cancer Drug submarkets, with respect to key regions.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Small Molecule Cancer Drug are as follows: History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025 This report includes the estimation of market size for value (million US$) and volume (K Pcs).
